MALVERN, Pa., May 28, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that data from the phase 1 randomized placebo controlled clinical study of SHAPE (SHP 141) in Stage IA –IIA Cutaneous T Cell Lymphoma will be presented at the American Society of Clinical Oncology meeting to be held in Chicago from May 30– June 3, 2014.
Help employers find you! Check out all the jobs and post your resume.
